Introduction
The t(8;21)(q22;q22) is the most common translocation in de novo acute myeloid leukemia (AML) occurring in up to 20% of adult and 40% of pediatric cases of AML-M2. 1, 2 The translocation fuses AML1 on chromosome 21 with ETO (eight twenty-one)/MTG8 on chromosome 8 to produce the AML1/ETO fusion gene located on the derivative 8 chromosome. 3, 4 For patients with this disease, there is a substantial clinical and cytogenetic complete response rate with initial chemotherapy, but up to 40% of patients still relapse and many die. The analysis of minimal residual disease, theoretically, offers the possibility of identifying patients who are either cured or, conversely, likely to relapse with the possibility of making appropriate adjustments in therapy.
Clustering of the 8;21 translocation breakpoints permits the fusion transcript to be readily detected by RT-PCR. In most, or even all, patients in long-term remission, the AML1/ETO fusion transcript can still be detected. [5] [6] [7] [8] Thus, non-quantitative methodologies cannot be used to justify additional toxic therapy for patients in remission. Quantitative RT-PCR assays for AML1/ETO have been successfully implemented using blood and bone marrow samples. [9] [10] [11] Recently, Tobal et al 12 reported that absolute levels of AML1-MTG8(ETO) could be correlated with impending relapse. However, the clinical utility of MRD testing remains unproven and requires standardized, validated protocols. In addition, contamination is an ever present concern for PCR-based tests, especially when dealing with MRD and potentially life-threatening therapies.
Cytogenetic analysis provides an alternative approach to MRD assessment. While high numbers of metaphase spreads can be examined by fluorescence in situ hybridization (FISH), 13 the use of FISH on interphase cells with locus-specific probes has higher sensitivity. The most significant limitation to this approach, however, has been false positives resulting from random overlapping signals when probes from only one side of each chromosomal breakpoint were used (reviewed in Varella-Garcia 14 ). To overcome this problem in t(8;21) AML, we developed a probe set (D-FISH AML1/ETO) that utilized probes from each side of both translocation breakpoints. 15 This produced two fusion signals from the derivative chromosomes, as well as two discrete signals from the remaining normal alleles, resulting in a marked reduction in false positives as has been reported with other D-FISH probes. [15] [16] [17] With the near elimination of false positive signals in interphase cells, we have undertaken an analysis of MRD. Our results demonstrate that residual positive cells, in the range of 1-4 per 2000 (0.05-0.19%), can be identified in bone marrow from a majority of patients in hematologic and cytogenetic remission. However, in two patients in early clinical relapse we found that the number of t(8;21) cells was initially only 0.6% in one case and 1.0% in the other. This indicated that the large majority of BM cells in these two instances were non-leukemic and suggested that an enrichment strategy was required to increase the sensitivity of the test. Since false positives with the D-FISH probe set were negligible, and because most t(8;21) AMLs express the cell surface marker CD34, we wondered if cell sorting combined with FISH might provide that enrichment. What emerged from these studies was perhaps more interesting. We were able to obtain fresh material suitable for cell sorting in one patient who was examined after 2 months of clinical and cytogenetic remission although still receiving chemotherapy. At this initial time point, we observed that 80% of the CD34 + selected cells contained the 8;21 translocation, a 17-fold enrichment over unselected bone marrow cells. This patient was followed with repeated analyses and by 5 months after obtaining CR, there was no enrichment in t(8;21) cells following CD34 + selection. These results suggest that the residual t(8;21) cells were undergoing differ-entiation as evidenced by the loss of CD34 positivity, a finding which is in agreement with previous in vitro colony assays. 8 Thus, the use of cell-sorting combined with a specific and quantitative assessment of the t(8;21) translocation, such as the D-FISH probe set, may provide an indirect assessment of the differentiation state of residual t(8;21) cells.
Materials and methods

Patient samples
Samples from 29 patients, obtained from cytogenetic laboratories at seven institutions were available for study. All patients had been diagnosed with AML-M2 and had initially obtained cytogenetic and hematologic remission. All had initial classical cytogenetic analysis showing the t(8;21)(q22;q22) at diagnosis. For 20 patients, bone marrow aspirates were available from a single remission time point. For the others, bone marrow samples were available from multiple (2-6) time points including some with residual disease. As positive controls, bone marrow aspirates from 18 patients at diagnosis or relapse were analyzed. As negative controls, 22 bone marrow specimens from patients with non-hematological diseases and normal karyotypes were examined.
FISH
Slides were submitted to a dual-color, dual-target FISH assay as previously described 15 with modifications. Briefly, after the bone marrow cells were fixed and dropped on to microscope slides, they were washed for 1 min in 70% acetic acid, then dehydrated and denatured in 70% formamide/2× SSC at 72°C for 3-4 min. The AML1 DNA (encompassing the 21q22 breakpoint) was labeled by nick translation with d-UTP Rhodal Green and the ETO DNA (encompassing the 8q22 breakpoint) was labeled with d-UTP Texas red. The probe was denatured and applied to a selected area of the slides. These areas were covered with glass coverslips and sealed with rubber cement. Hybridization was allowed to occur for 24 h at 37°C. Post-hybridization washes were performed with 50% formamide/2× SSC (three 6 min washes), 2× SSC and 2× SSC/0.1% NP40 (one 6 min wash in each) at 46°C. After rinsing in PBS, the slides were stained with DAPI (0.15 g/ml in Vectashield, Vector Laboratories, Burlingame, CA, USA). Analysis was performed on an Olympus BX60 fluorescence microscope (Olympus America, Lake Success, NY, USA) using single interference filter sets of red (Texas red), green (FITC), blue (DAPI) and a dual (red/green) band pass filter. Each assay included one to three slides from bone marrow specimens of patients in remission. In addition, slides from bone marrow specimens of patients with active disease, or from healthy or non-leukemic individuals, were used as positive and negative controls, respectively. Analyses were performed in two laboratories: the Cytogenetics Core at the University of Colorado Cancer Center and the Cytogenetics Laboratory at the City of Hope National Medical Center. In each laboratory, coded slides were scored by two independent observers. Approximately 2000 single, intact nuclei were scored per specimen and representative cells from each specimen were imaged using a Quips XL Genetics Workstation (Vysis, Downers Grove, IL, USA). The following scoring criteria were applied: Red (R, representing ETO) and green (G, representing AML1) Leukemia signals appearing as discrete elements were scored as single signals. Red and green signals which overlapped, were touching or were closely adjacent were scored as fused (F) signals. Negative nuclei were those which displayed two red signals and two green signals with no fused signal (2R2G0F). Similarly, nuclei displaying 1R1G1F or 0R0G2F were scored as negative, since they were likely to represent random co-localization events. Positive nuclei were identified as those containing either: (1) one red, one green and two fused signals (1R1G2F); (2) 
Results
Ninety-four bone marrow specimens were analyzed. These consisted of specimens from 29 t(8;21) AML patients who had initially obtained clinical and cytogenetic remission (CR), 19 patients with untreated or relapsed t(8;21) AML (positive controls) and 22 patients without AML with normal karyotypes (negative controls). The frequency of cells with the 8;21 translocation in the positive controls ranged from 75% to 100%. In the negative controls, a total of 44 000 cells were scored and two cells (0.0045%) displaying the pattern of two fused and two normal alleles (1R1G2F) were found. These two cells came from different individuals with no evidence of hematologic disease. Whether they represent true t(8;21) translocations in the absence of disease, or are due to other reasons, is unknown.
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Minimal residual disease assessment
The detailed results for each patient are presented in Table 1 . The clinical status at the time of examination is indicated. In some instances, we had information regarding the subsequent clinical outcome although in most cases this was not avail- Five specimens from patients in CR were collected after bone marrow transplantation. Four of these were analyzed within the first month post-transplant: three displayed positive cells and the fourth was negative. A fifth patient was negative 10 months after transplant. Patient 11 provides an example where FISH, if used, might have influenced the clinical decision making. In this case, a single metaphase out of 40 contained the 8;21 translocation whereas only one of 1972 interphase cells were subsequently found to be positive by FISH. On the basis of the metaphase analysis, the patient was considered to be in cytogenetic relapse and was transplanted. Following the transplant, positive cells were still detected by FISH. While it is not known whether the presence of a single positive metaphase in this context portends clinical relapse, our analysis suggests that the positive metaphase cell was not reflective of an overall increase in the t(8;21) population.
Higher numbers of positive cells were seen in two clinical settings. Patient 29, as mentioned, was first studied at 2 months after achieving clinical and cytogenetic remission. At this time, the percentage of positive interphase cells was 1.56% (Table 1) whereas at diagnosis it was 84% (not shown). With subsequent analysis, during periods of ongoing chemotherapy, this value varied substantially but finally dropped to 0.15%. In contrast, we analyzed four specimens from two patients in early clinical relapse. In these cases, the percentage of t(8;21)-positive cells ranged from 0.6% to 3.8%, far less than what was observed in our positive controls which ranged from 75 to 100%. For patient 17, the initial relapse sample contained 8.3% blasts (normal Ͻ5%) while the corresponding FISH study identified 0.61% cells with the t(8;21) translocation. Thus, this was an early relapse from a clinical standpoint, but one that was also detectable from a morphologic examination of the bone marrow. In summary, residual t(8;21) cells can be detected at levels of 0.05% to 0.19% in approximately 60% of remission patients using the D-FISH AML1/ETO probes. An exception may be patients in early clinical remission, or perhaps patients who are still receiving chemotherapy (see below). Levels of positive cells of 0.6% and greater are associated with relapse.
Use of cell sorting for CD34 to enrich the population of residual t(8;21) cells
While the D-FISH AML1/ETO probes were sensitive, normal BM cells provided a high background and obscured the detection of t(8;21) cells. For example, patient 10 was in clinical relapse yet only 1% of the cells contained the 8;21 translocation. Also, patients 20 and 23 had negative tests 30 days following bone marrow transplant yet they relapsed 61 and ෂ70 days later, respectively. While it is possible that the disease was more aggressive in the patients who underwent bone marrow transplant, patients 21 and 22 relapsed 4-6 months Leukemia after a negative test. Thus, it seemed clear that either an enrichment or additional information was required to render the MRD analysis more useful.
Because most cases of t(8;21) leukemia express CD34, 18, 19 we used fluorescence activated cell sorting to enrich for the t(8;21) population. This was carried out using fresh cells from patient 29, a pediatric case who was first studied 2 months after achieving clinical and cytogenetic remission. As can be seen in Figure 1 , the low side-scatter gate of the mononuclear cell fraction contained approximately 9% CD34 + cells ( Figure  1b) . As this fraction removed approximately 30% of the more mature CD34
− cells (Figure 1a) , the value of CD34 + cells in the unselected bone marrow was 6.9% (see Discussion). Subsequent sorting enriched the CD34 + cell population to over 95% (Figure 1c ). Cytospins were prepared from these populations and analyzed by FISH. Strikingly, 80% of the CD34 + cells contained the 8;21 translocation (Table 1, Figure 2d ) compared to 4.6% of the pre-sorted cells, a 17-fold enrichment. However, subsequent analyses done at approximately 3.5 and 5 months from the time of complete remission showed less effect (Table 1 ). In fact, by 5 months there was no enrichment at all. Whereas 0.15% of the unsorted BM cells were t(8;21) positive, only 0.06% of the sorted CD34
+ cells contained the translocation (specimen F6, Table 1 ). This indicated that the t(8;21) cells were losing the CD34 marker.
From the percentages of cells in the unsorted and sorted populations, we could determine how many t(8;21) cells retained the CD34 marker which would occur if they were leukemic or undifferentiated. Conversely, loss of CD34 expression occurs during differentiation. In the initial unsorted sample, the percentage of CD34 + cells was 6.9% and CD34 + cell sorting enriched this population by 14.5-fold. If all the t(8;21) cells continued to express CD34, their numbers should probably increase from 4.6% to 67%. In fact, as predicted, the actual measured values ranged from 75 to 80% on three separate counts using varying cell dilutions. This strongly suggests that all the t(8;21) cells were CD34 + and therefore either leukemic or substantially undifferentiated. The last bone marrow was obtained 5 months from the time of initial clinical and cytogenetic remission and after two additional courses of chemotherapy. In this sample, the percentage of unsorted CD34 + cells was 1.4% and the t(8;21) population represented 0.15% of the bone marrow cells. CD34 + cell sorting, therefore, would have enriched the t(8;21) population by 70-fold (ie to 10%). However, the observed percentage of t(8;21) cells was only 0.06%. This indicates that only one out of 167 t(8;21) cells continued to express CD34. Thus, nearly all the residual t(8;21) cells were undergoing differentiation as evidenced by loss of CD34 expression. These results are in agreement with a previous report using in vitro colony assays and RT-PCR which indicated that residual t(8;21) cells from patients in long-term remission appeared to undergo normal differentiation (see Discussion). Thus, the combination of CD34 + selection plus FISH appears to provide an indirect, in vivo quantitative assessment of the proportion of residual t(8;21) cells undergoing differentiation.
Atypical FISH patterns associated with standard t(8;21)(q22;q22) karyotypes
Lastly, based on FISH staining patterns, we observed two cases of apparent 8;21 translocation variants although only limited cell pellets were available which prevented further studies. In the first case (P14, Figure 2a) , there was one fused signal and one pair of signals that were close but never touching. In metaphase chromosomes, the AML1 derived green signal was smaller than usual in the derivative 8 chromosome and appeared larger in the derivative 21 chromosome (not shown). This staining pattern might occur, for example, if the AML1 breakpoint occurred in a more 5Ј position of the gene. The persistent small gap between the red and green signals might be due to repetitive sequences blocked by Cot-1 DNA. In the second case (P17, Figure 2b ), cells positive for the translocation had one fused signal as well as one red (ETO) and two green (AML1) signals. This pattern might be caused by a threeway translocation and subsequent loss of 5Ј-ETO sequences which are not felt to contribute to the pathogenesis of this disease. For comparison, the typical pattern seen with the 8;21 translocation is shown in Figure 2c .
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Discussion
Our results demonstrate that the D-FISH AML1/ETO probe set is highly specific and can be used to detect and quantitate residual t(8;21) cells in a majority of patients with this disease. A major advantage of these probes is the low number of false positives (2/44 000). While single-fusion probes have false positive rates in the order of 3% due to random overlapping signals, D-FISH probes which recognize both sides of both translocation breakpoints are substantially more specific as is the case with this probe set. [15] [16] [17] While the clinical utility of monitoring MRD is unclear, MRD detection without quantitation is insufficient since longterm survival with positive cells has been convincingly demonstrated in t(8;21) AML. 5, 7, 8 This is not unique to t(8;21) AML as persistence of the PML-RAR␣ fusion transcript, resulting from the 15;17 translocation, has also been associated with long-term remission. 20 Quantitative RT-PCR has been the most common approach to analyze MRD. [9] [10] [11] [12] Because of the nature of the samples available to us (cell pellets from cytogenetic laboratories), it was not possible to directly compare the sensitivity of these FISH probes with RT-PCR. However, in a few cases (Table 1) , non-quantitative RT-PCR results were available. One case (P25) was positive in both tests whereas three cases (P22, P26, and P28) were negative by FISH and positive by PCR. The remaining specimen (P27) was reported to be negative by PCR, but we found it positive by FISH. With optimal single or nested primers it is almost certain that RT-PCR is more sensitive. On the other hand, for the roughly 60% of patients that had positive cells by FISH the quantitation was direct and simple, free of contamination and independent of transcription levels.
As an initial attempt to increase the sensitivity of the FISH assay, we incorporated CD34+ selection as most cases of t(8;21) AML express CD34. 18, 19 In one local patient for which we could obtain fresh cells for cell sorting, 80% of the CD34+ cells were positive for the 8;21 translocation 2 months after the patient had achieved clinical and standard cytogenetic remission. There are at least two possibilities which might explain this high value. One possibility would be that there were simply more residual leukemic cells than were recognized morphologically or by standard metaphase cytogenetic analysis. A second possibility could be that the hematopoietic stem cells containing the 8;21 translocation might have a proliferative advantage in the setting of chemotherapy induced bone marrow hypoplasia and subsequent repopulation. This patient had received chemotherapy 3 weeks prior to the analysis and the unsorted CD34 + population was also elevated at 6.9%. With regard to the second hypothesis, the AML1/ETO(MTG8) protein has been shown to upregulate the G-CSF receptor by its effects on CCAAT/enhancer binding protein epsilon. 21 Also, Rhoades et al 22 observed that while the AML1/ETO knock-in mouse did not develop leukemia, there was abnormal maturation and proliferation of hematopoietic progenitor cells. In addition, Cai et al 23 demonstrated that haploinsufficiency of AML1 resulted in the early appearance of hematopoietic stem cells in the aorta-gonad-mesonephros region and yolk sac. Thus, in the setting of increased G-CSF or other regulatory factors it is possible, albeit speculative, that the CD34 + cells expressing AML1/ETO would be able to outcompete their normal counterparts.
We also observed in this same patient that the CD34 + selection performed 3 months later failed to provide any enrichment in t(8;21) cells. In fact, the number of positive cells was actually less ( 8 who used combined flow sorting, in vitro colony assays and nested RT-PCR to show that hematopoietic stem cells, as well as monocytes and B cells, from patients in long-term remission contained the 8;21 translocation. In addition, these investigators identified AML1/ETOpositive colonies from the period of overt leukemia that were differentiated and indistinguishable from those derived from non-leukemic precursors. Thus, there seems to be two populations of t(8;21) cells present initially, one which is leukemic and the other which is a precursor.
In summary, the D-FISH AML1/ETO probe set is sensitive, specific and can be used to quantitate MRD in a majority of patients. However, the value of MRD determination remains to be determined. We propose, based on limited observations, that CD34
+ sorting combined with FISH may provide an indirect, in vivo assessment of the differentiation state of residual t(8;21) cells. This will require further testing and it will be important to determine if the frequency of CD34 + t(8;21) cells is affected by chemotherapy induced hypoplasia and regeneration. Lastly, most AMLs are derived from a leukemic stem cell having a CD34 + , CD38 − phenotype, while the majority of blasts are CD34 + , CD38
+ . 24, 25 With the availability of clonal markers, such as the AML1/ETO and other D-FISH probe sets, it may be useful to quantitatively analyze these or other distinct populations during the course of a patient's disease.
